Many of yesterdays trade ideas appear to be poised for continued growth in the coming trading sessions. Read below for updates and new picks for tomorrows session. Futures Prices (%) … [Read more...] about Trade-Ideas Tuesday, Oct. 22nd, 2019
Scynexis (NASDAQ: SCYX) is a clinical stage biotech company based out of New Jersey. The company has one significant drug under development in multiple indications, ibrexafungerp, for the treatment of … [Read more...] about In a Tough Environment for Biotechs, Can the Science at Scynexis Win?
Friday, October 11, 2019 About: ADVERUM BIOTECHNOLOGIES INC (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, ADVM is set … [Read more...] about Incoming Data + Gartley
As the month of October begins and broader markets sold off, biotech stocks are still largely negative and/ or flat for the year. As seen in the LABU vs. LABD chart below, the spread between the two … [Read more...] about Biotech: Time To Buy the Bull
This year has been full of positive catalysts for REGENXBIO Inc. (Nasdaq: RGNX). As RGNX continues to build out their clinical pipeline, data catalyst from upcoming phase 2a report on their Wet-AMD … [Read more...] about Upcoming Data And Technical Setup
Puma Biotechnology (NASDAQ: PBYI) is a commercial stage company with an approved oncology drug called Nerlynx, for the treatment of HER2+ breast cancer. The drug was first approved in July 2017, and … [Read more...] about Puma: Surviving, Not Thriving